Brief: Vimian Group Enters Partnership With Biotechnology Company Angany Inc.
Nov 23 (Reuters) - Vimian Group AB VIMIAN.ST :
* VIMIAN GROUP ENTERS PARTNERSHIP WITH BIOTECHNOLOGY COMPANY
ANGANY INC. TO DEVELOP NOVEL VACCINES FOR ALLERGY AND ATOPIC
DERMATITIS IN COMPANION ANIMALS
* TOTAL PAYMENTS FROM VIMIAN GROUP TO ANGANY DURING
DEVELOPMENT
PERIOD ARE ESTIMATED TO USD 20 MILLION
Source text for Eikon: ID:nMFN8QtqtV
Further company coverage: VIMIAN.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Vimian AB
See all newsSweden's Vimian Q3 revenue rises 15%, beats estimates
Brief: Vimian Q3 Adjusted EBITA EUR 29.2 Million Vs. IBES Estimate EUR 28.2 Million
Brief: Vimian Group To Buy Norfolk Medical Products In US
Brief: Vimian Group To Issue And Repurchase Over 2.6 Mln Shares For LTIP 2026
Sweden's Vimian Q2 revenue, adjusted EBITA beat expectations